Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062623 | 0.85 | PEPD (0.80) | PEPDGAAMAPTGFERALDH1A1 | |
| Urea SCHEMBL4746502 | 0.84 | EPHX2 (0.65) | GAAMAPTALDH1A1NPC1MEN1 | |
| SCHEMBL14047972 | 0.84 | PEPD (0.64) | PEPDGAAMAPTGFERALDH1A1 | |
| 4-Guanidino-Benzoic Acid SCHEMBL211005 | 0.83 | F2 (0.57) | ALDH1A1MEN1KMT2AMITFTP53 | |
| SCHEMBL1110923 | 0.83 | ALDH1A1 (0.63) | GAAMAPTALDH1A1NPC1MEN1 | |
| SCHEMBL4745756 | 0.81 | EPHX2 (0.71) | GAAMAPTALDH1A1NPC1MEN1 | |
| SCHEMBL9555249 | 0.81 | ALDH1A1 (0.61) | ALDH1A1NPC1MEN1KMT2AMITF | |
| 4-Guanidino-Benzoic Acid SCHEMBL273175 | 0.81 | F2 (0.55) | ALDH1A1MEN1KMT2AMITFTP53 | |
| SCHEMBL21082715 | 0.81 | RAB9A (0.69) | PEPDGAAMAPTGFERALDH1A1 | |
| 4-Guanidino-Benzoic Acid SCHEMBL22127093 | 0.81 | F2 (0.55) | ALDH1A1MEN1KMT2AMITFTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239903-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RETENTION OF PSMA-TARGETED THERAPY | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-12-14 | — | — | WO | claimed |
| CN-111205453-B | Polyamide containing 1, 3-dimethyl-1, 3-diphenylurea structure and preparation method thereof | 吉林大学 | 2021-04-30 | — | — | CN | claimed |
| CN-111205453-A | Polyamide containing 1, 3-dimethyl-1, 3-diphenylurea structure and preparation method thereof | 吉林大学 | 2020-05-29 | — | — | CN | claimed |
| CN-1732161-A | 1,3-diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARM INC (US) | 2006-02-08 | — | — | CN | claimed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | claimed |
| WO-2023239903-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RETENTION OF PSMA-TARGETED THERAPY | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-110997627-B | Cyst amide derivatives | 亥姆霍兹感染研究中心有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023076586-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| EP-0628033-A1 | BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
| US-4966901-A | FOR TREATMENT OF ALZHEIMER*S DISEASE, LEARNING OR MEMORY PROBLEMS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1990-10-30 | — | — | US | disclosed |
| EP-0346683-A1 | Pyrrole derivatives, their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1989-12-20 | — | — | EP | disclosed |
| US-4837225-A | ENCEPHALOTROPIC AND PSYCHOTROPIC EFFECTS | CASSELL AKTIENGESELLSCHAFT (DE) | 1989-06-06 | — | — | US | disclosed |
| EP-0213326-A1 | 2,5-Dimethyl pyrrole derivatives, their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1987-03-11 | — | — | EP | disclosed |
| US-4001218-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
| US-3982011-A | ANTIBIOTICS, ANIMAL GROWTH PROMOTERS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-21 | — | — | US | disclosed |
| US-3931153-A | BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | PEPD 66/4885GAA 2916/4885MAPT 3731/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | PEPD 2302/4885GAA 2947/4885MAPT 718/4885 |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | PEPD 278/4885GAA 324/4885MAPT 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.